Abstract
We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 microg/kg (n=9) or 2 microg/kg (n=14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-gamma release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by low doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response.
Copyright 2000 Academic Press.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / pharmacology*
-
Carcinoma, Basal Cell / drug therapy
-
Female
-
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology*
-
Head and Neck Neoplasms / drug therapy
-
Humans
-
Interferon-gamma / metabolism
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-10 / metabolism
-
Interleukin-6 / biosynthesis
-
Interleukin-8 / biosynthesis
-
Leukocytes / drug effects
-
Lipopolysaccharides / pharmacology
-
Male
-
Middle Aged
-
Recombinant Proteins / pharmacology*
-
Sialoglycoproteins / metabolism
-
Teichoic Acids / pharmacology
-
Time Factors
Substances
-
Antineoplastic Agents
-
IL1RN protein, human
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-6
-
Interleukin-8
-
Lipopolysaccharides
-
Recombinant Proteins
-
Sialoglycoproteins
-
Teichoic Acids
-
Interleukin-10
-
lipoteichoic acid
-
Interferon-gamma
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
molgramostim